Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    XmAb13676
Previous Study | Return to List | Next Study

Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02924402
Recruitment Status : Recruiting
First Posted : October 5, 2016
Last Update Posted : September 14, 2020
Sponsor:
Collaborator:
ICON Clinical Research
Information provided by (Responsible Party):
Xencor, Inc.

Brief Summary:
The purpose of this study is to determine the safety and tolerability of intravenous (IV) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).

Condition or disease Intervention/treatment Phase
B-cell Non-Hodgkins Lymphoma Chronic Lymphocytic Leukemia Biological: XmAb13676 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 216 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This study will enroll two parallel disease groups in escalation: patients with non-CLL B cell malignancies and patients with CLL/SLL/Richter's Transformation.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients With CD20-Expressing Hematologic Malignancies
Actual Study Start Date : October 2016
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : October 2025


Arm Intervention/treatment
Experimental: Non-CLL B Cell Malignancies (Group NHL)
XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
Biological: XmAb13676
Biological

Experimental: CLL/SLL (Group CLL)
XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
Biological: XmAb13676
Biological




Primary Outcome Measures :
  1. Safety as determined by the number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: Baseline Day 1 through Day 56 ]
  2. Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb13676 dosing [ Time Frame: Baseline Day 1 through Day 56 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Able to provide written informed consent
  • Diagnosis of either Non-CLL B cell malignancy or CLL/SLL
  • Ineligible for or have exhausted standard therapeutic options and have relapsed or refractory disease
  • ECOG performance status 0-2
  • Fertile patients must agree to use highly effective contraception during and for 4 weeks after last dose of XmAb13676
  • Able and willing to complete the entire study

Additional Patient Inclusion Criteria for the DLBCL Cohort (Expansion Phase)

  1. Histologically confirmed diagnosis (specified by 2016 World Health Organization) of DLBCL or transformed low-grade lymphoma with measurable disease
  2. Patient must be refractory or have relapsed after 2 or more standard therapeutic options, at least one of which must have included anti-CD20 antibody therapy.
  3. Not a candidate for or refusing treatment with hematopoietic stem cell transplantation

Additional Patient Inclusion Criteria for the Follicular Lymphoma Cohort (Expansion Phase)

  1. Diagnosis of follicular lymphoma Grades 1-3a
  2. Patient must be ineligible for or have exhausted standard therapeutic options and have had 2 or more prior systemic regimens.

Additional Patient Inclusion Criteria for the Mantle Cell Lymphoma Cohort (Expansion Phase)

  1. Diagnosis of mantle cell lymphoma
  2. Patient must be ineligible for or have exhausted standard therapeutic options and have had 2 or more prior systemic regimens.

Additional Patient Inclusion Criteria for the Waldenström Macroglobulinemia Cohort (Expansion Phase)

  1. Diagnosis of Waldenström macroglobulinemia
  2. Patient must be ineligible for or have exhausted standard therapeutic options and have had 2 or more prior systemic regimens.

Additional Patient Inclusion Criteria for Richter Transformation Cohort (Expansion Phase)

1. Diagnosis of Richter transformation Additional Patient Inclusion Criteria for Other Indolent Lymphomas Cohort (Expansion Phase)

  1. Diagnosis of other indolent B-cell, non-Hodgkin's lymphomas, specifically the following: MALT lymphoma, nodal marginal zone lymphoma, and splenic marginal zone lymphoma (NOTE: SLL is not eligible)
  2. Patient must be ineligible for or have exhausted standard therapeutic options and have had 2 or more prior systemic regimens.

Exclusion Criteria:

  • Cytotoxic chemotherapy, radiotherapy, or immunotherapy including other anti-CD20 antibodies within 4 weeks, or small molecule or investigational agents within 6 elimination half-lives of the first dose of XmAb13676
  • Prior allogeneic stem cell or solid organ transplantation
  • Failure to recover from Grade 3 or 4 toxicity from previous treatment
  • Multiple myeloma/plasma cell leukemia or B cell acute lymphoblastic leukemia
  • Known intolerance to CD20 monoclonal antibody therapy
  • History of primary central nervous system lymphoma or neoplastic central nervous system disease
  • Platelet count < 50 x 10^9/L
  • Absolute neutrophil count < 1.0 x 10^9/L
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) at screening > 3x upper limit of normal (ULN)
  • Bilirubin > 1.5 mg/dL unless prior diagnosis and documentation of ongoing hemolysis or Gilbert's syndrome has been made)
  • Estimated creatinine clearance < 50 40 mL/min
  • Active/uncontrolled autoimmune disease
  • Clinically significant cardiac/cardiovascular disease, or pulmonary compromise
  • Seizure disorder
  • History of stroke with the past year6 mos prior to study entry
  • History or evidence of a clinically unstable/uncontrollable disorder, condition or disease other than primary malignancy, that in the opinion of the Investigator would pose a risk to the patient safety or interfere with the study evaluation, procedures or completion
  • Evidence of any serious bacterial, viral, parasitic or systemic fungal infections within the 30 days prior to study entry
  • Positive test for human immunodeficiency virus (HIV) or hepatitis C (HCV) antibodies (unless HCV viral load test by PCR is negative)
  • Positive test for HbsAg, or positive test for HBcAb (unless serology is positive due to recent intravenous immunoglobulin therapy). HBcAb positivity will be allowed if HBsAb is present.
  • Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study visit
  • Positive urine pregnancy test (ie, urine human chorionic gonadotropin) at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02924402


Contacts
Layout table for location contacts
Contact: David Liebowitz, MD 858-617-6160 ext 260 dliebowitz@xencor.com
Contact: Chelsea Johnson 858-480-3891 ext 159 cjohnson@xencor.com

Locations
Show Show 18 study locations
Sponsors and Collaborators
Xencor, Inc.
ICON Clinical Research
Investigators
Layout table for investigator information
Study Director: David Liebowitz, MD VP, Clinical Oncology, Clinical Development, Xencor, Inc.
Layout table for additonal information
Responsible Party: Xencor, Inc.
ClinicalTrials.gov Identifier: NCT02924402    
Other Study ID Numbers: XmAb13676-01
First Posted: October 5, 2016    Key Record Dates
Last Update Posted: September 14, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Xencor, Inc.:
NHL
B-cell Prolymphocytic Leukemia
Transformed Lymphoma
Burkitt's Lymphoma
Mantle Cell Lymphoma
Hairy Cell Leukemia
Splenic Marginal Zone Lymphoma
Waldenstrom's Macroglobulinemia
Variant Hairy Cell Leukemia
Splenic B-cell Lymphoma/Leukemia
Lymphoplasmacytic Lymphoma
Extranodal Marginal Zone Lymphoma (MALT)
MALT Lymphoma
Nodal Marginal Zone Lymphoma
Follicular Lymphoma
In Situ Follicular Neoplasia
Duodenal-type Follicular Lymphoma
Large B-cell Lymphoma with IRF4 rearrangement
Primary Cutaneous Follicle Center Lymphoma
Diffuse Large B-cell Lymphoma
DLBCL
T-cell/Histiocyte-Rich Large B-cell Lymphoma
Primary Cutaneous DLBCL, leg type
EBV-positive DLBCL, NOS
EBV-positive Mucocutaneous Ulcer
DLBCL Associated with Chronic Inflammation
Lymphomatoid Granulomatosis
Primary Mediastinal (Thymic) Large B-cell Lymphoma
Intravascular Large B-cell Lymphoma
ALK+ Large B-cell Lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Hematologic Neoplasms
Lymphoma, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Leukemia, B-Cell
Neoplasms by Site
Hematologic Diseases